Fujifilm Medical Systems USA has formally launched a tomosynthesis biopsy capability as an option on its Aspire Cristalle digital mammography system at AHRA's annual meeting this week in Denver.
First showcased at RSNA 2018, the new option serves as an addition to the traditional stereotactic biopsy method and utilizes tomosynthesis guidance to calculate 3D coordinates of a suspicious lesion in the breast, enabling targeting of lesions that were previously undetectable on full-field digital mammography images alone, according to the vendor.
Fujifilm believes that tomosynthesis biopsy will enable radiologists to accurately complete biopsy of suspicious areas, as well as realize higher clinical confidence and increased efficiency.
